|
1
|
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
|
Nat Biotechnol
|
2010
|
3.15
|
|
2
|
Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake.
|
Pharmacol Biochem Behav
|
2002
|
1.75
|
|
3
|
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
|
Mol Cancer Ther
|
2006
|
1.64
|
|
4
|
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
|
Clin Cancer Res
|
2013
|
1.18
|
|
5
|
Discovery of a potent and selective aurora kinase inhibitor.
|
Bioorg Med Chem Lett
|
2008
|
1.15
|
|
6
|
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
|
J Pathol
|
2012
|
1.15
|
|
7
|
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
|
Mol Cancer Ther
|
2013
|
1.03
|
|
8
|
A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice.
|
Psychopharmacology (Berl)
|
2002
|
0.99
|
|
9
|
The corticotropin-releasing factor/urocortin system and alcohol.
|
Alcohol Clin Exp Res
|
2002
|
0.88
|
|
10
|
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.
|
J Clin Invest
|
2013
|
0.84
|
|
11
|
Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.
|
Eur J Pharmacol
|
2002
|
0.84
|